33 RENO: A European surveillance registry of coronary brachytherapy with the NovosteTM Beta-CathTM System

in Radiotherapy & Oncology (2001), 60(supp 1), 12

Young Investigators Workshop participants (P.A Coucke) and N. Coleman : Radiation Research program, Radiation Oncology Sciences Program, National Cancer Institue, Nih, August 1-2, 2000

in International Journal of Radiation, Oncology, Biology, Physics (2001), 49(5), 1505-1516

INTRODUCTION The one-and-a-half day Young Investigators Workshop was held in the Holiday Inn, Bethesda, August 1–2, 2000. Using the SCAROP mailing list and recommendations from department chiefs ... [more ▼]

INTRODUCTION The one-and-a-half day Young Investigators Workshop was held in the Holiday Inn, Bethesda, August 1–2, 2000. Using the SCAROP mailing list and recommendations from department chiefs, approximately 55 “early-career” physicianscientists were invited to attend the workshop. Table 1 includes the participants. The goals of the meeting were: c To bring together radiation oncology physician-scientists who were in the early part of their career to discuss research ideas and opportunities as well as potential barriers to progress for the field and for young-investigator careers. c To help develop camaraderie among and a critical-mass of a new generation of physician-scientists with interests ranging from technology development, to basic and translational research, to outcomes research and analysis. c To help the young investigators gain familiarity with the NIH grant programs. c To prepare a “white paper” with their vision and ideas for potential opportunities for the future. If possible, a shortand long-term agenda were to be proposed. The first morning included presentations from a variety of NCI programs. Three breakout sessions were held in the afternoon. Breakout Group Reports were discussed by the entire group the following morning. A fourth discussion topic on “Barriers To a Successful Research Career” was conducted by the entire group. Drafts of this entire Workshop Report were circulated to the participants. The final document represents the efforts of the entire Young Investigators Workshop and provides the perspective from the point of view of the investigators who have many years to invest in the future of radiation oncology. The Radiation Research Program (RRP) is grateful to all the participants for a lively workshop and to the session co-chairs for the timely preparation of this report. [less ▲]

Pathology and outcome after HART

in Strahlentherapie und Onkologie (2000)

Combination of FMdC, Tirapazamine (SR4233) and irradiation in vitro

in International Journal of Radiation, Oncology, Biology, Physics (2000), 46(3),

Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis?

in European Journal of Cancer (2000), 37(2), 198203

To assess the prognostic factors and the outcome in patients with squamous-cell carcinoma of the penis, a retrospective review of 41 consecutive patients with non-metastatic invasive carcinoma of the ... [more ▼]

To assess the prognostic factors and the outcome in patients with squamous-cell carcinoma of the penis, a retrospective review of 41 consecutive patients with non-metastatic invasive carcinoma of the penis, treated between 1962 and 1994, was performed. The median age was 59 years (range: 35–76 years). According to the International Union Against Cancer (UICC) 1997 classification, there were 12 (29%) T1, 24 (59%) T2, 4 (10%) T3 and 1 TX (2%) tumours. The N-classification was distributed as follows: 29 (71%) patients with N0, 8 (20%) with N1, 3 (7%) with N2 and 1 (2%) with N3. Forty-four per cent (n=18) of the patients underwent surgery: partial penectomy with (n=4) or without (n=12) lymph node dissection, or total penectomy with (n=1) or without (n=1) lymph node dissection. 23 patients were treated with radiation therapy alone, and all but 4 of the patients who were operated upon received postoperative radiation therapy (n=14). The median follow-up period was 70 months (range 20–331 months). In a median period of 12 months (range 5–139 months), 63% (n=26) of the patients relapsed (local in 18, locoregional in 2, regional in 3 and distant in 3). Local failure (stump in the operated patients, and the tumour bed in those treated with primary radiation therapy) was observed in 4 out of 16 (25%) patients treated with partial penectomy ±postoperative radiotherapy versus 14 out of 23 (61%) treated with primary radiotherapy (P=0.06). 15 (83%) out of 18 local failures were successfully salvaged with surgery. In all patients, 5- and 10-year survival rates were 57% (95% confidence interval (CI), 41–73%) and 38% (95% CI, 21–55%), respectively. The 5-year local and locoregional rates were 57% (95% CI, 41–73%) and 48% (95% CI, 32–64%), respectively. In patients treated with primary radiotherapy, 5- and 10-year probabilities of surviving with penis preservation were 36% (95% CI, 22–50%) and 18% (95% CI, 2–34%), respectively. In multivariate analyses, survival was significantly influenced by the N-classification, and surgery was the only independent factor predicting the locoregional control. We conclude that, in patients with squamous-cell carcinoma of the penis, local control is better in patients treated with surgery. However, there seems to be no difference in terms of survival between patients treated by surgery and those treated by primary radiotherapy ±salvage surgery, with 39% having organ preservation. [less ▲]

Radiosurgery with Linac and Micro Multi-Leaf Collimator (mMLC)

in European Journal of Neurology (2000), 142(10), 1188

Effect of grade on disease-free survival and overall survival in FIGO Stage I adenocarcinoma of the endometrium.

in European Journal of Obstetrics & Gynecology & Reproductive Biology (2000), 88

Abstract Objective : To analyse the effect of differentiation on disease-free survival (DFS) and overall survival (OS) in patients with stage I adenocarcinoma of the endometrium. Patients and methods ... [more ▼]

Abstract Objective : To analyse the effect of differentiation on disease-free survival (DFS) and overall survival (OS) in patients with stage I adenocarcinoma of the endometrium. Patients and methods : From 1979 to 1995, 350 patients with FIGO stage IA–IC with well (G1), moderately (G2) or poorly (G3) differentiated tumors were treated with surgery and high dose-rate brachytherapy with or without external radiation. Median age was 65 years (39–86 years). Results : The 5-year DFS was 8863% for the G1 tumors, 7764% for the G2 tumors, and 6767% for the G3 tumors (P50.0049). With regard to the events contributing to DFS, the 5-year cumulative percentage of local relapse was 4.6% for the G1 tumors, 9.0% for the G2 tumors, and 4.6% (P50.027) for the G3 tumors. Cumulative percentage of metastasis was 1.4, 6.3 and 7.2% (P,0.001), respectively, whereas percentages of death were 6.0, 7.9 and 20.7% (P,0.001). The 5-year OS was 9163, 8364 and 7667%, respectively (P50.0018). In terms of multivariate hazard ratios (HR), the relative differences between the three differentiation groups correspond to an increase of 77% of the risk of occurrence of either of the three events considered for the DFS (HR51.77, 95% Cl [0.94–3.33]), (P50.078) for the G2 tumors and of 163% (HR52.63, 95% Cl [1.27–5.43]), (P50.009) for the G3 tumors with respect to the G1 tumors. The estimated relative hazards for OS are, respectively, in line with those for DFS: HR51.51 (P50.282) for the G2 tumors; and HR53.37 (P50.003) for the G3 tumors. Conclusion : Patients with grade 1 tumors are those least exposed to either local relapse, metastasis, or death. In contrast patients with grade 2 tumors seem to be at higher risk of metastasis, whereas patients with grade 3 tumors appear at higher risk of death. Since we have looked at the first of three competing events (local relapse, metastasis and death), this suggests that patients with grade 3 tumors probably progress to death so fast that local relapse, if any, cannot be observed. Ó 2000 Elsevier Science Ireland Ltd. All rights reserved. [less ▲]

Basic rules of dosimetry in endovascular brachytherapy.

in Journal of Interventional Cardiology (2000), 13(6), 425-429

Endovascular brachytherapy after percutaneous coronary intervention (PCI), is becoming a standard approach for the treatment and prevention of restenosis. A variety of technical approaches are currently ... [more ▼]

Endovascular brachytherapy after percutaneous coronary intervention (PCI), is becoming a standard approach for the treatment and prevention of restenosis. A variety of technical approaches are currently available to deliver ionizing irradiation to the vascular target. Basically two kinds of radioactive isotopes are available that emit gamma radiation (photons) or beta radiation (electrons). The pitfalls and solutions for the optimization of dosimetry are discussed. As might be expected, the inhomogeneous dose distribution across the target volume results in recurrence by underdosage or in complications because of overdosage. Moreover, uniformization of the target definition and reporting of the dose distribution in endovascular brachytherapy is a prerequisite for comparison between the results of the various clinical trials and is absolutely necessary to improve the therapeutic efficacy of this new approach in the prevention of restenosis after coronary angioplasty with or without stenting. (J Interven Cardiol2000; 13:425430) [less ▲]

Congrès SASRO 1999

in Strahlentherapie und Onkologie (1999, March)

Radio-oncologie et radiothérapie. Confirmation de l'efficacité des radiations ionisantes en oncologie, et renouveau de leur intérêt dans les affections non oncologiques : Acquisitions thérapeutiques 1998

in Médecine et Hygiène (1999), 54(2238), 100-111

En 1998, plusieurs études ont clarifié ou confirmé l'effet positif de la radiothérapie dans le cancer du sein in situ, dans différents types de lymphomes non hodgkinien et hodgkinien, et dans le cancer ... [more ▼]

En 1998, plusieurs études ont clarifié ou confirmé l'effet positif de la radiothérapie dans le cancer du sein in situ, dans différents types de lymphomes non hodgkinien et hodgkinien, et dans le cancer bronchique à petites cellules. Deux métaanalyses par contre semblent remettre en cause la radiothérapie, dans la maladie de Hodgkin de stade avancé et dans l'approche postopératoire du cancer ronchique à non petites cellules. Ces méta-analyses comportent toutefois d'importantes faiblesses et doivent être interprétées de façon critique. Dans le domaine technique de la radio-oncologie, les progrès spectaculaires de la planification assistée par ordinateur et l'intégration de l'imagerie IRM peuvent maintenant s'appliquer aussi à la curiethérapie. Enfin, la radiothéraple dans les affections non oncologiques suscite un nouvel intérêt, comme par exemple la curiethérapie intracoronarienne, un traitement prometteur pour prévenir la resténose coronarienne. [less ▲]